A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis

NCT06118619 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2023-11-09

No results posted yet for this study

Summary

The main purpose of testing: To confirm the effectiveness and safety of the drug Ingaron when used in patients hospitalized at the research center for various reasons.

Conditions

  • Respiratory Tuberculosis

Interventions

DRUG

Interferon-Gamma

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Sponsors & Collaborators

  • SPP Pharmaclon Ltd.

    lead INDUSTRY

Principal Investigators

  • Anatoly I Saulin, Master · SPP Pharmaclon Ltd.

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-12-31
Completion
2024-03-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118619 on ClinicalTrials.gov